Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt;–EGFR Inhibition in Colorectal Cancer

Rona Yaeger; Riccardo Mezzadra; Jenna Sinopoli; Yu Bian; Michelangelo Marasco; Esther Kaplun; Yijun Gao; HuiYong Zhao; Arnaud Da Cruz Paula; Yingjie Zhu; Almudena Chaves Perez; Kalyani Chadalavada; Edison Tse; Sudhir Chowdhry; Sydney Bowker; Qing Chang; Besnik Qeriqi; Britta Weigelt; Gouri J. Nanjangud; Michael F. Berger; Hirak Der‐Torossian; Kenna Anderes; Nicholas D. Socci; Jinru Shia; Gregory J. Riely; Yonina R. Murciano‐Goroff; Bob T. Li; James G. Christensen; Jorge S. Reis‐Filho; David B. Solit; Elisa de Stanchina; Scott W. Lowe; Neal Rosen; Sandra Misale

doi:10.1158/2159-8290.30849259

Abstract

Characterization of acquired resistance in vitro models

Related Publications

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

James Bean , Gregory J. Riely , Marissa N. Balak +4 more

Abstract Purpose: Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are associated with sensitivity of lung adenocarcinomas to ...

2008 Clinical Cancer Research 276 citations

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis , Michael E. Goldberg , Danielle Greenawalt +66 more

Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups o...

2018 Cancer Discovery 1505 citations

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

Nikhil Wagle , W. Marston Linehan , Michael F. Berger +9 more

A detailed understanding of the mechanisms by which tumors acquire resistance to targeted anticancer agents should speed the development of treatment strategies with lasting cli...

2011 Journal of Clinical Oncology 988 citations

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong , Marwan Fakih , John H. Strickler +31 more

Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-rela...

2020 New England Journal of Medicine 1570 citations

Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

Takayuki Kosaka , Yasushi Yatabe , Hideki Endoh +3 more

Abstract Recently it has been reported that mutations in the tyrosine kinase domain of the epidermal growth factor receptor(EGFR) gene occur in a subset of patients with lung ca...

2004 Cancer Research 1218 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

Download PDF (Free) View on DOI.org

Social Impact

Altmetric

Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

CrossRef

Cite This

APA Style

                            
                                    Rona Yaeger, 
                                
                                    Riccardo Mezzadra, 
                                
                                    Jenna Sinopoli
                                
                                et al.
                            
                            (2025). 
                            Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt;–EGFR Inhibition in Colorectal Cancer. 
                            
                            .
                            https://doi.org/10.1158/2159-8290.30849259

Identifiers

DOI: 10.1158/2159-8290.30849259

Data Quality

Data completeness: 70%

Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer